IO-112 is under clinical development by IO Biotech and currently in Phase I for Head And Neck Cancer Squamous Cell Carcinoma. According to GlobalData, Phase I drugs for Head And Neck Cancer Squamous Cell Carcinoma have a 79% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how IO-112’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IO-112 is under development for the treatment of essential thrombocythemia and polycythemia vera, relapsed/refractory metastatic solid tumors including breast cancer, colorectal cancer, head and neck cancer squamous cell carcinoma, melanoma, ovarian cancer, and transitional cell cancer (urothelial cell cancer). It is administered through subcutaneous route.. It is developed based on T-win technology. The drug candidate is an immune modulatory vaccine containing a single arginase derived peptide targeting Arginase 1 (ARG1).
IO Biotech overview
IO Biotech is a biotechnology company, which develops disruptive immune modulating anti-cancer drugs. The company is investigating IO102 vaccine, against non-small cell lung cancer (NSCLC); IO130, a PD-L1 inhibitor targeting basal cell carcinoma of the skin; IO112 vaccine, to treat solid tumors; IO140, an immune modulatory vaccine containing a single CCL22 derived peptide, against ovarian cancer; and IO160, a neo antigen vaccine to treat myeloproliferative neoplasms (MPN). It utilizes T-win technology platform to discover, design, and validate new immune modulating vaccine candidates. The company is a spin off from the Center for Cancer Immune Therapy (CCIT), University of Copenhagen Herlev Hospital. IO Biotech is headquartered in Copenhagen, Denmark.
For a complete picture of IO-112’s drug-specific PTSR and LoA scores, buy the report here.